Autor: |
Roshanzamir F; Department of Bioinformatics, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, 6619-14155, Iran.; Systems and Synthetic Biology, Department of Biology and Biological Engineering, Chalmers University of Technology, SE-412 96, Gothenburg, Sweden., Robinson JL; National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Department of Biology and Biological Engineering, Chalmers University of Technology, SE-41258 Gothenburg, Sweden., Cook D; Systems and Synthetic Biology, Department of Biology and Biological Engineering, Chalmers University of Technology, SE-412 96, Gothenburg, Sweden., Karimi-Jafari MH; Department of Bioinformatics, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, 6619-14155, Iran., Nielsen J; Systems and Synthetic Biology, Department of Biology and Biological Engineering, Chalmers University of Technology, SE-412 96, Gothenburg, Sweden.; BioInnovation Institute, DK-2200 Copenhagen, Denmark. |
Abstrakt: |
Triple negative breast cancer (TNBC) metastases are assumed to exhibit similar functions in different organs as in the original primary tumor. However, studies of metastasis are often limited to a comparison of metastatic tumors with primary tumors of their origin, and little is known about the adaptation to the local environment of the metastatic sites. We therefore used transcriptomic data and metabolic network analyses to investigate whether metastatic tumors adapt their metabolism to the metastatic site and found that metastatic tumors adopt a metabolic signature with some similarity to primary tumors of their destinations. The extent of adaptation, however, varies across different organs, and metastatic tumors retain metabolic signatures associated with TNBC. Our findings suggest that a combination of anti-metastatic approaches and metabolic inhibitors selected specifically for different metastatic sites, rather than solely targeting TNBC primary tumors, may constitute a more effective treatment approach. |